Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Biomarkers, Novel Agents Continue to Advance Multiple Myeloma Treatment

November 11th 2015

Shaji Kumar, MD, discusses how newly approved agents and other changes have affected the treatment of multiple myeloma and what is on the horizon for the disease.

Willem Overwijk Explains the Role of the Innate Immune System in Cancer Treatment

November 6th 2015

Willem Overwijk, PhD, Associate Professor, Department of Melanoma Medical Oncology, Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the role of innate immunity in the treatment of cancer.

Combinations Key to Optimizing Novel Antibodies in Myeloma

November 4th 2015

Optimizing outcomes with novel antibodies in multiple myeloma will involve combination regimens with established agents.

Dr. Landgren Discusses MRD Detection for Multiple Myeloma

November 4th 2015

C. Ola Landgren, MD, PhD, hematologic oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses minimal residual disease detection for progression-free survival and overall survival for patients with multiple myeloma.

FDA Issues Complete Response Letter for CE-Melphalan in Myeloma

October 23rd 2015

The FDA issued a complete response letter to Spectrum Pharmaceuticals, informing the company that its new drug application (NDA) for the use of Captisol-enabled melphalan in multiple myeloma will not be approved in its current form.

Future Role for HDAC Inhibition in Multiple Myeloma

October 15th 2015

Emerging Therapies in Multiple Myeloma

October 15th 2015

Clinical Experience With Panobinostat in Multiple Myeloma

October 15th 2015

Triplet Therapy for Relapsed/Refractory Multiple Myeloma

October 15th 2015

HDAC Inhibitors in Multiple Myeloma

October 15th 2015

Integrating Agents in Relapsed/Refractory Multiple Myeloma

October 15th 2015

Treating Double-Refractory Multiple Myeloma

October 15th 2015

Therapeutic Sequencing in Multiple Myeloma

October 15th 2015

Third-Line Options for Multiple Myeloma

October 15th 2015

Treatment Approaches for Relapsed/Refractory Multiple Myeloma

October 15th 2015

Pathogenesis of Multiple Myeloma

October 15th 2015

Experts Share Hopes for the Future of Myeloma Treatment

October 14th 2015

The data being amassed about novel multiple myeloma therapies have the potential to change the way patients with relapsed or refractory disease are currently being treated.

Dr. Kumar on Defining Multiple Myeloma

October 12th 2015

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, gives an overview on the expanded definition of multiple myeloma.

Expert Optimistic About Achieving Cure for Myeloma

September 29th 2015

Five years from now multiple myeloma will have a therapeutic backbone consisting entirely of combinations of novel agents.

Carfilzomib Granted Priority Review for Relapsed Multiple Myeloma

September 18th 2015

The FDA has granted a priority review designation to carfilzomib in combination with dexamethasone for patients with relapsed multiple myeloma following prior treatment with at least one therapy.

x